Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):480–486. doi: 10.1054/bjoc.2000.1345

Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL -2-mediated neovascularization

L Boldrini 1, A Calcinai 1, E Samaritani 1, F Pistolesi 1, A Mussi 2, M Lucchi 2, C A Angeletti 2, F Basolo 1, G Fontanini 1
PMCID: PMC2374649  PMID: 10945495

Abstract

Recent in vivo and in vitro studies have demonstrated a wide spectrum of biologic activities of cytokines in the pathogenesis and progression of malignancy. Tumour necrosis factor alpha (TNF-α) and transforming growth factor beta (TGF-β) have emerged as two of the many host-derived mediators that seem to interfere with both antiproliferative and tumorigenic effects in malignant tumours including lung cancer. However, their association with tumour prognosis or prognostic factors has not yet been completely clarified. In this study, we assessed TNF-α and TGF-β mRNA expression by RT-PCR technique in 61 NSCLC samples, demonstrating the presence of TNF-α and TGF-β mRNA in 55.74% and 45.9% of cases, respectively. We also evaluated the expression of the two distinct transmembrane TNF receptors. TNFR-I and TNFR-II, with a PCR-positive signal in 70.49% and 65.57% of cases, respectively. In 49 of the 61 cases, we evaluated the prognostic impact of the two growth-inhibiting factors using the Kaplan–Meier analysis. In the univariate analysis patients without nodal metastatic involvement (P = 0.02), less advanced tumour stage (P = 0.02) or TNF-α and TGF-β positive cancers (P = 0.01 and P = 0.03) showed a favourable prognosis in terms of overall survival. Since our previous studies demonstrated a significant association between NSCLC behaviour, neoangiogenesis and bcl -2 expression, we investigated the putative relation between TNF-α and TGF-β on the one hand, and vascular count (as a measure of tumour angiogenesis) and bcl -2 protein expression, on the other hand. Our results showed a significant direct association between TNF-α and bcl -2 (P = 0.05) and an inverse association between TNF-α and microvessel count (P = 0.03). Moreover, as previously demonstrated, we observed a significant inverse correlation between bcl -2 protein expression and vascular count (P = 0.05), suggesting that the favourable effect of TNF-α on clinical outcome may be related to a bcl -2-mediated low neovascular development. © 2000 Cancer Research Campaign

Keywords: NSCLC, tumour necrosis factor alpha, transforming growth factor beta, angiogenesis, prognosis

Full Text

The Full Text of this article is available as a PDF (155.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auvinen P., Lipponen P., Johansson R., Syrjänen K. Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2627–2631. [PubMed] [Google Scholar]
  2. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 1;1032(1):89–118. doi: 10.1016/0304-419x(90)90014-r. [DOI] [PubMed] [Google Scholar]
  3. Boldrini L., Calcinai A., Silvestri V., Basolo F., Lucchi M., Mussi A., Angeletti C. A., Bevilacqua G., Fontanini G. Quantitation by competitive PCR assay of vascular endothelial growth factor in non-small cell lung carcinomas. Int J Oncol. 1999 Jan;14(1):161–168. doi: 10.3892/ijo.14.1.161. [DOI] [PubMed] [Google Scholar]
  4. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  5. Derynck R., Jarrett J. A., Chen E. Y., Eaton D. H., Bell J. R., Assoian R. K., Roberts A. B., Sporn M. B., Goeddel D. V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985 Aug 22;316(6030):701–705. doi: 10.1038/316701a0. [DOI] [PubMed] [Google Scholar]
  6. Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D., Allison A. C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992 Mar;140(3):539–544. [PMC free article] [PubMed] [Google Scholar]
  7. Fajardo L. F., Prionas S. D., Kwan H. H., Kowalski J., Allison A. C. Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern. Lab Invest. 1996 Mar;74(3):600–608. [PubMed] [Google Scholar]
  8. Fontanini G., Boldrini L., Vignati S., Chinè S., Basolo F., Silvestri V., Lucchi M., Mussi A., Angeletti C. A., Bevilacqua G. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer. 1998 Apr;34(5):718–723. doi: 10.1016/s0959-8049(97)10145-9. [DOI] [PubMed] [Google Scholar]
  9. Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., De Placido S., Basolo F., Angeletti C. A., Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997 Jun 18;89(12):881–886. doi: 10.1093/jnci/89.12.881. [DOI] [PubMed] [Google Scholar]
  10. Fox S. B., Westwood M., Moghaddam A., Comley M., Turley H., Whitehouse R. M., Bicknell R., Gatter K. C., Harris A. L. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer. 1996 Feb;73(3):275–280. doi: 10.1038/bjc.1996.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heim M. E., Siegmund R., Illiger H. J., Klee M., Rieche K., Berdel W. E., Edler L. Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie. 1990 Dec;13(6):444–447. doi: 10.1159/000216817. [DOI] [PubMed] [Google Scholar]
  12. Hennet T., Bertoni G., Richter C., Peterhans E. Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res. 1993 Mar 15;53(6):1456–1460. [PubMed] [Google Scholar]
  13. Hong W. S., Jett J. R., Sasaki Y., Takahashi H., Nakano H., Nakagawa K., Hoshi A., Saijo N. Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. Jpn J Clin Oncol. 1987 Mar;17(1):49–55. [PubMed] [Google Scholar]
  14. Kemeny N., Childs B., Larchian W., Rosado K., Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer. 1990 Aug 15;66(4):659–663. doi: 10.1002/1097-0142(19900815)66:4<659::aid-cncr2820660410>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  15. Koukourakis M. I., Giatromanolaki A., O'Byrne K. J., Whitehouse R. M., Talbot D. C., Gatter K. C., Harris A. L. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer. 1997 Dec 19;74(6):565–570. doi: 10.1002/(sici)1097-0215(19971219)74:6<565::aid-ijc1>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  16. Leek R. D., Landers R., Fox S. B., Ng F., Harris A. L., Lewis C. E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer. 1998 Jun;77(12):2246–2251. doi: 10.1038/bjc.1998.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lippman M. E., Dickson R. B., Gelmann E. P., Rosen N., Knabbe C., Bates S., Bronzert D., Huff K., Kasid A. Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem. 1987 Sep;35(1):1–16. doi: 10.1002/jcb.240350102. [DOI] [PubMed] [Google Scholar]
  18. Liénard D., Lejeune F. J., Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg. 1992 Mar-Apr;16(2):234–240. doi: 10.1007/BF02071526. [DOI] [PubMed] [Google Scholar]
  19. McCune B. K., Mullin B. R., Flanders K. C., Jaffurs W. J., Mullen L. T., Sporn M. B. Localization of transforming growth factor-beta isotypes in lesions of the human breast. Hum Pathol. 1992 Jan;23(1):13–20. doi: 10.1016/0046-8177(92)90004-m. [DOI] [PubMed] [Google Scholar]
  20. Miles D. W., Happerfield L. C., Naylor M. S., Bobrow L. G., Rubens R. D., Balkwill F. R. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer. 1994 Mar 15;56(6):777–782. doi: 10.1002/ijc.2910560603. [DOI] [PubMed] [Google Scholar]
  21. Mizukami Y., Nonomura A., Yamada T., Kurumaya H., Hayashi M., Koyasaki N., Taniya T., Noguchi M., Nakamura S., Matsubara F. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res. 1990 Sep-Oct;10(5A):1115–1126. [PubMed] [Google Scholar]
  22. Munker M., Munker R., Saxton R. E., Koeffler H. P. Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res. 1987 Aug 1;47(15):4081–4085. [PubMed] [Google Scholar]
  23. Murray P. A., Barrett-Lee P., Travers M., Luqmani Y., Powles T., Coombes R. C. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer. 1993 Jun;67(6):1408–1412. doi: 10.1038/bjc.1993.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Naylor M. S., Stamp G. W., Foulkes W. D., Eccles D., Balkwill F. R. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest. 1993 May;91(5):2194–2206. doi: 10.1172/JCI116446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ohkura M., Fuchimoto S., Orita K. Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha. Jpn J Cancer Res. 1990 Oct;81(10):1026–1031. doi: 10.1111/j.1349-7006.1990.tb03341.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pezzella F., Jones M., Ralfkiaer E., Ersbøll J., Gatter K. C., Mason D. Y. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer. 1992 Jan;65(1):87–89. doi: 10.1038/bjc.1992.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993 Sep 2;329(10):690–694. doi: 10.1056/NEJM199309023291003. [DOI] [PubMed] [Google Scholar]
  28. Pusztai L., Clover L. M., Cooper K., Starkey P. M., Lewis C. E., McGee J. O. Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer. 1994 Aug;70(2):289–292. doi: 10.1038/bjc.1994.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rubbert A., Manger B., Lang N., Kalden J. R., Platzer E. Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer. 1991 Aug 19;49(1):25–31. doi: 10.1002/ijc.2910490106. [DOI] [PubMed] [Google Scholar]
  30. Schiller J. H., Bittner G. Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines. Int J Cancer. 1990 Jul 15;46(1):61–66. doi: 10.1002/ijc.2910460113. [DOI] [PubMed] [Google Scholar]
  31. Silvestrini R., Costa A., Lequaglie C., Mochen C., Veneroni S., Leutner M., Ravasi G. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch. 1998 May;432(5):441–444. doi: 10.1007/s004280050188. [DOI] [PubMed] [Google Scholar]
  32. Sporn M. B., Roberts A. B., Wakefield L. M., Assoian R. K. Transforming growth factor-beta: biological function and chemical structure. Science. 1986 Aug 1;233(4763):532–534. doi: 10.1126/science.3487831. [DOI] [PubMed] [Google Scholar]
  33. Tran T. A., Kallakury B. V., Ambros R. A., Ross J. S. Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer. 1998 Jul 15;83(2):276–282. [PubMed] [Google Scholar]
  34. Ueki N., Nakazato M., Ohkawa T., Ikeda T., Amuro Y., Hada T., Higashino K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta. 1992 Oct 27;1137(2):189–196. doi: 10.1016/0167-4889(92)90201-l. [DOI] [PubMed] [Google Scholar]
  35. Walker R. A., Dearing S. J. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer. 1992;28(2-3):641–644. doi: 10.1016/s0959-8049(05)80116-9. [DOI] [PubMed] [Google Scholar]
  36. Yang S. C., Owen-Schaub L., Grimm E. A., Roth J. A. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother. 1989;29(3):193–198. doi: 10.1007/BF00199995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES